About 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)
MFAM Research
- [BUY] 4D Molecular Therapeutics (NASDAQ: FDMT) – One-Time Gene Therapy Heads Into a Defining Phase 3 Readout in Wet AMDOctober 16, 2026Buy rated by institutional sell-side research with a US$32.00 target, 148.6 per cent upside, ahead of Phase 3 wet AMD gene therapy data in 2Q27.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARFinancial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Biotechnology |
|---|---|